BioSpace News Archive

CannTrust Holdings Inc. released preliminary operational and financial results for the quarter ended March 31, 2019.

Eagle’s bendamustine 500mL hydrochloride injectable will be sold as BELRAPZO beginning June 3, 2019

CannTrust Holdings Inc. announced that it has commenced an underwritten public offering of an aggregate US$200 million common shares, which contemplates approximately 85% of the common shares to be sold in the offering by the Company and approximately 15% of the common shares to be sold in the offering by certain shareholders.

The Government of the province of Saskatchewan has informed treating physicians that it will grant access to SPINRAZA™ to patients living with Spinal Muscular Atrophy (SMA)

Rapha Capital Management, LLC, an investment management firm located in Miami, Florida, and their associated entities announced their participation in a Series C financing for Poseida Therapeutics.

TSMC and ANSYS enable power integrity and reliability multiphysics solutions for next-generation applications

Cambium Plant Sciences to disrupt cannabis industry through the development and licensing of next generation cannabis plant genetics and cultivation IP.

Aura Biosciences announced that two year clinical data from its ongoing Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the Company’s lead product candidate for the primary treatment of primary choroidal melanoma, will be highlighted in a poster presentation at the Association for Research in Vision and Ophthalmology 2019 Annual Meeting being held April 28-May 2, 2019, in Vancouver, British Columbia.

Novel Inflammasome inhibitor, which uniquely targets ASC, represents a differentiated approach to block abnormal immune responses driving the onset of inflammatory diseases

Moleculin Biotech, Inc. announced it will host a conference call to discuss its significant discovery for lung cancer, FDA Fast Track Designation and recent corporate events.